Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Hematology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1523909
This article is part of the Research Topic Infectious Diseases and Hematology: Diagnosis and Management - Volume II View all 7 articles

Risk Factors and Clinical Outcomes of Cytomegalovirus Infection Following Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Aplastic Anemia: A Single-Center Retrospective Study

Provisionally accepted
Jia Feng Jia Feng 1Xinhe Zhang Xinhe Zhang 1Zhengwei Tan Zhengwei Tan 1Yuechao Zhao Yuechao Zhao 2Huijin Hu Huijin Hu 2Junfa Chen Junfa Chen 2Liqiang Wu Liqiang Wu 2Qinghong Yu Qinghong Yu 2Dijiong Wu Dijiong Wu 2Baodong Ye Baodong Ye 2Wenbin Liu Wenbin Liu 2*
  • 1 Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
  • 2 Department of Hematology, First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China

The final, formatted version of the article will be published soon.

    Background:Cytomegalovirus (CMV) infection remains a critical cause of mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT), despite significant advancements in CMV prevention and treatment with the introduction and widespread use of Letermovir.However, in China, due to limitations in the availability and cost of medications, some patients still face challenges in accessing Letermovir. For this subset of the population, exploring the risk factors for CMV infection remains significant in predicting its occurrence. Methods:Therefore, a retrospective analysis was conducted on 88 haploidentical hematopoietic stem cell transplant recipients over 4 years. Results:Our study results indicate that chronic graft-versus-host disease (cGVHD) is an independent risk factor for CMV infection following Haplo-HSCT. Survival analysis reveals lower survival rates in the Refractory CMV Infection (RIC) group compared to the non-RIC group, with patients having lower viral loads demonstrating higher rates of seroconversion and improved survival under the same treatment regimen.:Strengthening the monitoring of CMV-DNA in post-transplant patients, actively promoting hematopoietic recovery, preventing the occurrence of CMV infection, and controlling the development of CMV infection can lead to better survival outcomes for patients with aplastic anemia undergoing Haplo-HSCT.

    Keywords: Cytomegalovirus infection, aplastic anemia, Haploidentical hematopoietic stem cell transplantation, Chronic graft-versus-host disease, immunology

    Received: 06 Nov 2024; Accepted: 13 Dec 2024.

    Copyright: © 2024 Feng, Zhang, Tan, Zhao, Hu, Chen, Wu, Yu, Wu, Ye and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wenbin Liu, Department of Hematology, First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.